Status:
UNKNOWN
Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
Brief Summary
The primary objective of this retrospective study was to assess the efficacy and safety of a bismuth quadruple regimen of a low-dose potassium-competitive acid blocker versus a standard-dose potassium...
Detailed Description
Helicobacter pylori (H. pylori) infection is closely associated with a variety of diseases including chronic gastritis, peptic ulcer, and gastric cancer. Adequate acid suppression is essential for H. ...
Eligibility Criteria
Inclusion
- Diagnosis of H. pylori infection confirmed by urea breath test, monoclonal fecal antigen test, endoscopic biopsy histopathology, or bacterial culture;
- No previous eradication therapy for H. pylori;
- Age and gender are not restricted.
Exclusion
- Use of acid-suppressing drugs within 2 weeks prior to treatment, or use of bismuth or antibiotics (including herbal medicines with antimicrobial properties) within 4 weeks prior to treatment;
- Known hypersensitivity to the drugs used in this study;
- History of esophageal or gastric surgery;
- Pregnant or lactating women;
- Serious systemic diseases, diseases of the heart, lungs, brain and other vital organs, hepatic or renal insufficiency or malignant tumors (except gastric cancer);
- Patients unable to express their main complaints.
Key Trial Info
Start Date :
September 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2024
Estimated Enrollment :
558 Patients enrolled
Trial Details
Trial ID
NCT06037122
Start Date
September 1 2023
End Date
June 1 2024
Last Update
September 14 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.